Amycretin could give Novo a buzzy product in a newly competitive obesity market. It works similarly to existing GLP-1 ...

Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...

G/O Media is once again attempting to use AI to churn out content — while simultaneously warning that anything the AI ...

In a healthcare market brimming with potential, DarioHealth Corp. * is quietly emerging as a standout player, combining cutting-edge technology with proven outcomes. Looking at recent achievements, it ...

In a report released today, Jo Walton from UBS maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of ...

Investors and analysts reacted immediately to Novo's revelation. The price of Novo's common stock declined dramatically. From ...

A/S, a global healthcare company specializing in diabetes care and other chronic conditions, has been at the forefront of the rapidly expanding GLP-1 market. With a market capitalization of $376.79 ...

For the 18th year running, Apple has been named Fortune’s Most Admired Company. The rankings are based of a survey of more than 3,000 company execs across 30 countries. While Apple’s number one ...

The company behind popular weight-loss drugs failed to disclose even more money it paid to healthcare groups and patient organisations , a pharmaceutical watchdog has said. Novo Nordisk - which ...

The Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.

Novo Nordisk's stock (NVO) rose more than 8% in Friday trading on news that the company's latest weight-loss product delivered favorable results. The new drug, amycretin, similar to the company's ...

Good news about an experimental weight-loss shot sent shares in Ozempic maker Novo Nordisk soaring, making it once again ...